LITTLE FALLS, N.J., June 15, 2012 /PRNewswire via COMTEX/ -- CANTEL MEDICAL CORP. /quotes/zigman/221338/quotes/nls/cmn CMN +1.14% announced today that its Board of Directors authorized a regular semiannual cash dividend of $0.0467 per outstanding share of the Company's Common Stock. The dividend is payable on July 31, 2012 to shareholders of record at the close of business on July 17, 2012.

Cantel Medical Corp. /quotes/zigman/221338/quotes/nls/cmn CMN +1.14% is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. For further information, visit the Cantel website at http://www.cantelmedical.com .

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

SOURCE Cantel Medical Corp.

Copyright (C) 2012 PR Newswire. All rights reserved

...

RONKONKOMA, N.Y., Jun 15, 2012 (BUSINESS WIRE) -- --Click here for video interviews

ReCor Medical, an emerging medical device company, reported today six-month follow-up data on eight patients who have been treated via renal denervation for their resistant hypertension with the Company's PARADISE(R) System--the only system for renal denervation that is based on ultrasound, not radiofrequency, energy.

At six months follow-up, the PARADISE data showed that office systolic blood pressure was reduced by an average of 33 mm Hg in 8 patients. Of note: there were also significant and sustained blood pressure reductions in home and ambulatory measurements at six months. The scientific literature demonstrates that only a 5 mm Hg reduction in BP results in a 14% decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in mortality.

"These clinical results strongly suggest a significant competitive advantage for ReCor's ultrasound-based PARADISE system compared to radiofrequency-based standard of care for treating resistant hypertension patients," said Mano Iyer, CEO, ReCor Medical.

The PARADISE ultrasound catheter was designed with the aim to allow complete circumferential denervation more consistently and efficiently than the standard of care radiofrequency ablation catheter. The procedure with the PARADISE system only requires 30 seconds of energy delivery per treatment location, thereby dramatically reducing the overall procedure time.

ReCor also announced that it has published a collection of video interviews conducted during 'EuroPCR 2012' with key opinion leaders (KOLs) on the topic of RENAL DENERVATION to treat resistant hypertension. (Click link above to see these videos.)

About ReCor Medical, Inc.

Founded in 2009, ReCor is a private venture-backed, early-stage company developing novel therapeutic ultrasound catheter technology. ReCor is backed by European and U.S. investors including Sofinnova Partners, one of the largest life science investors in Europe. The Company's PARADISE(TM) technology for renal denervation is CE-marked. For more information about ReCor Medical, please visit the Company's website at www.recormedical.com .

NOTE: PARADISE(TM) is approved for sale in Europe; it is not approved for sale or investigational use in the United States.

SOURCE: ReCor Medical

        
        Ronald Trahan Associates Inc. 
        Ronald Trahan, APR, +1-508-359-4005 x108 
        President
        

Copyright Business Wire 2012

...

...

Mortality in dialysis patients may not be associated with ESA dose: a ... 7thSpace Interactive (press release) Anaemia of chronic kidney disease increases the risk of death and adverse events, but can bemanaged using erythropoiesis stimulating agents (ESAs).

...